Comparison among Endoscopic Variceal Obliteration, Endoscopic Band Ligation, and Balloon-occluded Retrograde Transvenous Obliteration for Treatment of Gastric Variceal Bleeding.
10.4166/kjg.2011.57.5.302
- Author:
Seul Ki MIN
1
;
Sang Gyune KIM
;
Young Seok KIM
;
Jun Yong BAE
;
Jong Chan LEE
;
Sae Hwan LEE
;
Hong Soo KIM
;
Soung Won JEONG
;
Jae Young JANG
;
Jong Ho MOON
;
Moon Sung LEE
;
Boo Sung KIM
Author Information
1. Department of Internal Medicine, Soon Chun Hyang University School of Medicine, Bucheon, Korea. liverkys@schmc.ac.kr
- Publication Type:Original Article ; Comparative Study ; English Abstract
- Keywords:
Esophageal and gastric varices;
Gastrointestinal hemorrhage;
Liver cirrhosis;
Treatment
- MeSH:
Adult;
Aged;
*Balloon Occlusion;
Enbucrilate/therapeutic use;
Endoscopy, Gastrointestinal;
Esophageal and Gastric Varices/complications/*therapy;
Female;
Gastrointestinal Hemorrhage/complications/mortality/*therapy;
Humans;
Ligation;
Liver Cirrhosis/complications;
Male;
Middle Aged;
Recurrence;
Retrospective Studies;
Severity of Illness Index
- From:The Korean Journal of Gastroenterology
2011;57(5):302-308
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Endoscopic variceal obliteration (EVO), endoscopic variceal ligation (EVL), and balloon-occluded retrograde transvenous obliteration (BRTO) are used to manage gastric variceal bleeding. We compared the re-bleeding rates and survival times of these modalities. METHODS: The study enrolled 103 patients with suspected gastric variceal bleeding between July 2001 and May 2009. For the management of gastric variceal bleeding, 52 patients underwent EVO; 36, EVL; and 15, BRTO. We evaluated their laboratory results and vital signs, and calculated the Child score, Child classification, and Model for End-stage Liver Disease score. Rebleeding was defined as new-onset hematemesis, hematochezia, melena, or endoscopically proven bleeding. Time-to-rebleeding and survival time were examined by Kaplan-Meyer analysis. A value of p<0.05 indicated statistical significance. RESULTS: There were no significant differences in baseline characteristics among the three groups. The overall follow-up period averaged 65.13 months. During follow-up, rebleeding occurred in 17 patients (11 EVO, 5 EVL, and 1 BRTO). The times-to-rebleeding were 63.59, 75.79, and 51.41 months for EVO, EVL, and BRTO, respectively, and did not differ significantly (p=0.515). The median survival times were 77.42, 70.14, and 42.79 months, respectively, and also were not different significantly (p=0.978). CONCLUSIONS: There were no significant differences in the time-to-rebleeding or survival time among EVO, EVL, and BRTO. Further prospective, large-scale studies are needed.
